Alamar Biosciences Inc. (NASDAQ: ALMR) reported second-quarter revenue of $29.427 million, representing an 82% year-over-year increase and surpassing the consensus estimate of $25.94 million. The proteomics company narrowed its net loss to 22 cents per share, beating the consensus loss of 33 cents, while raising its fiscal 2026 sales guidance to $116 million-$120 million compared to the prior consensus of $113.259 million. Shares rose 33.78% to $37.20 on Tuesday, driven by strong consumable revenue growth and an expanded global partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures.

The financial performance was underpinned by nearly 150% year-over-year growth in consumable revenue, according to Yuling Luo, founder, CEO and chair of Alamar Biosciences. Management attributed the momentum to recent product launches, including the eMTBR-tau and the Immune 340 Panel, which have strengthened the company’s content menu and extended its reach into new disease areas. Luo stated that the company is well-positioned to sustain this momentum into the coming quarters.

Strategic Partnership Expansion

Alamar Biosciences is expanding its collaboration with the Alzheimer’s Disease Data Initiative and Gates Ventures to apply multiplex protein profiling across 86,000 additional samples. This strategic move aims to advance research from single biomarkers to a precision-medicine approach for understanding diseases. When completed in 2027, the combined dataset is expected to encompass more than 140,000 samples profiled across multiple geographies and cohorts, integrated with clinical and longitudinal outcome data.

Financial Performance Overview

What the Numbers Show

The divergence between revenue growth and margin improvement suggests a scaling effect in Alamar Biosciences’ operations. With consumable revenue growing nearly 150% year-over-year, the company is leveraging high-margin recurring revenue streams alongside its initial instrument sales. This mix shift supports the raised fiscal 2026 guidance, indicating that the current growth trajectory is sustainable beyond one-time equipment deployments.

Technical Outlook and Analyst Sentiment

Alamar Biosciences shares are trading significantly above their 20-day and 50-day simple moving averages (SMAs), at 21.4% and 29.4%, respectively. The 20-day SMA has crossed above the 50-day SMA, a bullish signal suggesting continued upward pressure. However, the Relative Strength Index (RSI) stands at 72.94, indicating overbought territory which could lead to a potential pullback or consolidation.

Key technical levels include resistance at $32.90 and support at $26.30, which aligns with the 20-day SMA. Analyst consensus remains positive with a Buy rating and an average price forecast of $32. Recent analyst actions include:

• JPMorgan: Overweight (Raises target to $35 on Aug. 11)
• Leerink Partners: Initiated with Outperform (Target $35 on May 12)
• TD Cowen: Initiated with Buy (Target $30 on May 12)

Alamar Biosciences Inc (NASDAQ: ALMR) announced on Aug 10, 2026, an expansion of its strategic partnership with the Alzheimer's Disease Data Initiative and Gates Ventures. The agreement adds profiling of 86,000 plasma samples using the company's NULISAseq Neuro 220 panel, moving the collaboration toward a combined dataset of more than 140,000 samples by 2027. This scale enables researchers to move beyond single biomarkers toward a precision-medicine understanding of disease heterogeneity, subtypes, and trajectories across diverse geographies.

The expanded agreement builds on a multi-center initiative announced in June 2025, which profiled over 55,000 samples using Alamar's NULISA technology. Approximately 21,000 of the new samples are part of a national-scale proteomics initiative launched with leading research universities in mid-July. The remaining samples will be profiled to complete the broader dataset, which will be integrated with clinical and longitudinal outcome data and shared through the secure infrastructure of the Alzheimer's Disease Data Initiative and the Global Neurodegeneration Proteomics Consortium.

Technical Scope and Biomarker Targets

The NULISAseq Neuro 220 panel measures approximately 220 neurological biomarker targets from small volumes of plasma or cerebrospinal fluid. It provides resolution for characterizing disease heterogeneity across neurodegeneration, neuroinflammation, synaptic function, and vascular pathology. Notably, the panel includes eMTBR-Tau, an emerging biomarker capable of measuring tau tangle burden from blood. This complements established markers like p-Tau217, enabling simultaneous blood-based capture of both hallmark Alzheimer's pathologies for the first time.

Strategic Implications

Dr Yuling Luo, founder, CEO and chair of Alamar Biosciences, stated that multiplex protein profiling allows researchers to examine multiple biological processes at once. "The goal shifts from detecting pathology to describing it: characterizing disease subtypes, determining stage, and tracking how trajectories evolve over time," Luo said. He emphasized that the expansion reflects scientific momentum and the value the NULISA platform delivers to the field.

Niranjan Bose, Managing Director of Health & Life Sciences at Gates Ventures and interim Executive Director of the Alzheimer's Disease Data Initiative, noted that this scale paired with deep clinical phenotyping offers an opportunity to understand how disease varies across individuals. "That kind of insight can change how we approach treatment and prevention," Bose said.

What the Numbers Show

The expansion represents a significant increase in data volume, adding 86,000 samples to the existing 55,000+. This nearly doubles the dataset size, positioning the project as potentially the largest study of neurodegenerative disease. The inclusion of eMTBR-Tau alongside p-Tau217 marks a technical shift from single-analyte investigation to simultaneous multi-pathology capture, which may enhance the predictive power of AI and machine learning models applied to the dataset.